Anti-metabolic plant peptides and their use

Abstract

To provide an anti-metabolic disorder plant peptide group, and to provide uses thereof.SOLUTION: The present invention provides an anti-metabolic disorder plant peptide group and uses thereof. Specifically, the anti-metabolic disorder plant peptide group disclosed in the present invention simultaneously possess the activity of controlling blood glucose, blood lipids, and blood pressure. Therefore, administering an effective amount of the anti-metabolic disorder plant peptide group to an individual can effectively prevent or ameliorate various metabolic disorders such as high blood pressure, high blood lipids, and high blood glucose. The anti-metabolic disorder plant peptide group is obtained by isolation from a primary product of plant raw materials.SELECTED DRAWING: Figure 12

Description

Technical Field

[0001] The present invention relates to a composition composed of low molecular weight proteins, and particularly relates to anti-metabolic disorder plant peptides and their uses.

Background Art

[0002] As modern people's awareness of health has increased, consumers not only purchase basic nutritional supplements such as vitamins and minerals, but also purchase nutritional supplements with specific functions according to their needs. With the progress of biotechnology, many manufacturers have obtained active ingredients with specific functions from foods through special manufacturing processes such as fermentation and hydrolysis, and then used them as active ingredients in nutritional supplements to enhance the effectiveness of health promotion.

[0003] According to statistics, in Taiwan, more than one-fourth of the people suffer from metabolic diseases such as hypertension, hyperglycemia, and hyperlipidemia. The causes of the above-mentioned metabolic diseases are not limited to genetics, but also related to an individual's diet and lifestyle. Imbalances between work and rest, major stress in life, lack of exercise, and a diet centered on fried foods also cause metabolic diseases. Although metabolic diseases do not have a significant impact on health in the short term, they can cause serious diseases such as stroke, heart disease, and diabetes in the long term. However, since it is not easy to change diet and lifestyle, many people choose to take nutritional supplements to control blood pressure, blood sugar, and blood lipids. However, in the current market, there is no nutritional supplement that can simultaneously improve blood pressure, blood sugar, and blood lipids.

Summary of the Invention

Problems to be Solved by the Invention

[0004] The primary objective of this invention is to provide a group of anti-metabolic plant peptides and their use. These anti-metabolic plant peptides contain multiple low-molecular-weight active peptides, and under the synergistic effect of their combined composition, they possess the ability to simultaneously control blood glucose, blood lipids, and blood pressure. Therefore, by administering the anti-metabolic plant peptides disclosed in this invention, it is possible to simultaneously and effectively improve or treat hypertension, hyperglycemia, and hyperlipidemia-related diseases. [Means for solving the problem]

[0005] To achieve the above objectives, the present invention discloses a group of anti-metabolic plant peptides, which are isolated from primary products of plant raw materials and comprise at least six low-molecular-weight peptides that can synergistically interact with each other. By controlling pathways such as the MAPK pathway and IRS / p-IR / PI3K / Akt pathway within an organism, these peptides can simultaneously improve or treat various metabolic diseases associated with imbalances in metabolic indicators such as blood pressure, blood lipids, and blood glucose.

[0006] Here, the primary product of the plant material is obtained by sequentially performing two extraction steps on the plant material: the first extraction step is a water extraction step, and the second extraction step is a supercritical fluid extraction step.

[0007] In other words, by administering an effective amount of the anti-metabolic plant peptide group disclosed in the present invention or a composition containing said anti-metabolic plant peptide group to an individual, it is possible to achieve the effect of simultaneously combating or improving various metabolic diseases, and in particular, diseases related to hypertension, hyperglycemia, and hyperlipidemia can be simultaneously treated or prevented. Here, the effective amount is at least 5 mg / kg / day.

[0008] In one embodiment of the present invention, the group of anti-metabolic plant peptides includes peptides with molecular sizes between 300 Da and 3000 Da, indicated in wavelength ranges (L1) to (L6) in a high-performance liquid chromatogram, where the retention time in wavelength range (L1) is 10.5 to 11.5 minutes, the retention time in wavelength range (L2) is 12.5 to 13.5 minutes, the retention time in wavelength range (L3) is 14.5 to 15.5 minutes, the retention time in wavelength range (L4) is 16.5 to 17.5 minutes, the retention time in wavelength range (L5) is 17.5 to 18.5 minutes, and the retention time in wavelength range (L6) is 24.5 to 25.5 minutes.

[0009] Here, the high-performance liquid chromatogram was obtained by performing a pretreatment step on the primary product of the plant raw material and then analyzing it using a high-performance liquid chromatograph under predetermined analytical conditions. The analytical conditions were as follows: the detection wavelength was 220 nm, the separation column was a C18 column (RP-C18), the column temperature was 60°C, eluent A was 5% acetonitrile containing 0.10% trichloroacetic acid, eluent B was 95% acetonitrile containing 0.085% trichloroacetic acid, and the mobile phase contained 10-20% eluent B used for 0-10 minutes, 20-30% eluent B used for 10-25 minutes, and 30-60% eluent B used for 20-60 minutes.

[0010] In another embodiment of the present invention, the pretreatment step includes dissolving the primary product of the plant raw material in 30% acetonitrile, performing ultrasonic extraction to obtain a supernatant, filtering the supernatant to obtain a filtrate, which is used for high-performance liquid chromatography.

[0011] In the pretreatment step described above, filtration is performed using a filter medium with voids of 0.20 to 0.25 μm, and the filter medium can be a filter membrane or a mesh screen.

[0012] In another embodiment of the present invention, the molecular size of the peptides included in the group of anti-metabolic plant peptides, indicated by wavelength ranges (L1) to (L6), is between 700 Da and 2400 Da. [Brief explanation of the drawing]

[0013] [Figure 1] The chromatographic analysis results of the peptide group (1) are shown, and the peptide group is a product extracted from bitter melon 1. [Figure 2] The chromatographic analysis results (2) of the peptide group are products extracted from watermelon 1. [Figure 3] The chromatographic analysis results of the peptide group (3) are shown, and the peptide group in question is a product extracted from watermelon 2. [Figure 4] The chromatographic analysis results of the peptide group (4) are shown, and the peptide group is a product extracted from pumpkin 1. [Figure 5] The chromatographic analysis results of the peptide group (5) are shown, and the peptide group in question is a product extracted from pumpkin 2. [Figure 6] The chromatographic analysis results of the peptide group (6) are shown, and the peptide group is a product extracted from bitter melon 2. [Figure 7] The chromatographic analysis results of the peptide group (7) are shown, and the peptide group is a product extracted from Trichosanthes cucumeroides 1. [Figure 8] The chromatographic analysis results of the peptide group (8) are shown, and the peptide group is a product extracted from Trichosanthes cucumeroides 2. [Figure 9] The chromatographic analysis results of the peptide group (9) are shown, and the peptide group is a product extracted from bitter melon 3. [Figure 10] The chromatographic analysis results of the peptide group (10) are shown, and the peptide group is a product extracted from bitter melon 4. [Figure 11] The chromatographic analysis results of the peptide group (11) are shown, and the peptide group is a product extracted from bitter melon 5. [Figure 12] Figure 1 shows a comparison between the chromatogram of the chromatogram measured for comparison samples 1-7. [Figure 13] This is an analysis of fasting blood glucose levels in each group of mice after the end of week 8 of the experiment. [Figure 14] It is the analysis result of glycated hemoglobin in blood after the end of the 8th week of the test for each group of mice. [Figure 15] It is the analysis result of fasting blood glucose level after the end of the 8th week of the test for each group of mice. [Figure 16] It is the analysis result of body weight after the end of the 8th week of the test for each group of mice. [Figure 17] It is the analysis result of body fat after the end of the 8th week of the test for each group of mice. [Figure 18] It is the analysis result of blood triglyceride after the end of the 8th week of the test for each group of mice. [Figure 19] It is the analysis result of total cholesterol in blood after the end of the 8th week of the test for each group of mice. [Figure 20] It is the analysis result of LDL cholesterol in blood after the end of the 8th week of the test for each group of mice. [Figure 21] It is the analysis result of postprandial blood glucose change for each group of subjects. [Figure 22] It is the analysis result of the area under the blood glucose curve at 2 hours after a meal for each group of subjects.

Mode for Carrying Out the Invention

[0014] The present invention discloses an anti-metabolic disorder plant peptide group and its use. Specifically, the anti-metabolic disorder plant peptide group disclosed by the present invention is obtained by separating from the primary product of plant raw materials, and the anti-metabolic disorder plant peptide group consists of peptides with a molecular size between 300 Da and 3000 Da shown in wavelength regions (L1) to (L6) with a retention time of 10.5 to 25.5 minutes in a high-performance liquid chromatogram.

[0015] Here, the high-performance liquid chromatogram is obtained by performing high-performance liquid chromatography under predetermined analysis conditions after performing a pretreatment process on the primary product of plant raw materials.

[0016] Specifically, the group of anti-metabolic plant peptides disclosed in the present invention is obtained by separating them from the primary product of a plant raw material, the primary product of the plant raw material is obtained by sequentially performing water extraction and supercritical fluid extraction on the plant raw material, and the plant raw material has at least one of the following properties: inhibiting dipeptidyl peptidase 4, inhibiting α-amylase, inhibiting GLUT2, inhibiting SGLT1, inhibiting α-glucosidase, or controlling insulin.

[0017] Here, the plant raw material in question is a type of gourd, such as watermelon, pumpkin, bitter melon, or gourd.

[0018] The group of anti-metabolic plant peptides disclosed in this invention has the ability to reduce blood glucose, blood pressure, blood lipids, and lipogenesis. Therefore, by administering an effective amount of the group of anti-metabolic plant peptides or a composition containing the group of anti-metabolic plant peptides to an individual, it is possible to achieve simultaneous and effective improvement of indicators related to metabolic diseases. This can lead to the alleviation or treatment of diseases related to hyperglycemia, hyperlipidemia, and hypertension, such as diabetes, kidney disease, hypertension, and dyslipidemia, and can also reduce the risk of developing complications or symptoms related to the aforementioned diseases.

[0019] The "primary product of plant raw materials" described in this invention refers to a product obtained by performing a process combining water extraction and supercritical fluid extraction on plant raw materials and removing residues and / or residuals, and it includes the group of anti-metabolic plant peptides disclosed in this invention.

[0020] The "plant raw materials" described in this invention include the genera Amaranthus, Phaseolus, Glycine, Avena, Cucurbitaceae, Cuminum, Chenopodium, Orus, Juglans, Hordeum, Spinacia, and Vigna. iThese are derived from plants classified as belonging to genera such as gna sp., wheat (Triticum sp.), flax (Linum sp.), reed (Phalaris sp.), horseradish (Moringa sp.), cacao (Theobroma sp.), and maize (Zea sp.), including bitter melon, snake gourd, cucumber, pumpkin, gourd, watermelon, live ginger, talcum powder (Trichosanthes cucumeroides), zinnia (Zinia elegans), alfalfa (Medicago truncatula), grapes, grapefruit, elderberry (Sambucus nigra), Arabidopsis thaliana, and rice.

[0021] The “composition” described in this invention refers to a composition containing 0.001% to 100% of the anti-metabolic plant peptides disclosed in this invention, and if the composition does not consist entirely of the anti-metabolic plant peptides disclosed in this invention, it further includes a vehicle and / or excipients acceptable in pharmaceuticals or foods. The composition can be prepared in various dosage forms as needed, such as tablets, powders, or aqueous solutions, and may be in various doses depending on parameters such as administration needs, target population, and frequency of administration. For example, the composition may be a nutritional supplement, a food, or a pharmaceutical.

[0022] The term "effective amount" as used in this invention refers to the minimum dose at which the group of anti-metabolic plant peptides disclosed in this invention exerts activity within an individual organism.

[0023] The anti-metabolic plant peptides disclosed in this invention can be stably isolated from various types of plant raw materials and simultaneously have the effects of lowering blood glucose, reducing body weight, reducing body fat, lowering blood triglycerides, lowering blood total cholesterol and blood LDL cholesterol, and lowering blood pressure. In other words, by administering an effective amount of the anti-metabolic plant peptides disclosed in this invention or a composition containing said anti-metabolic plant peptides to an individual, diseases caused by metabolic abnormalities of blood lipids, blood pressure, and blood glucose can be simultaneously and effectively alleviated or improved. By simultaneously preventing or improving various metabolic diseases, it is possible to reduce the discomfort that consumers feel when taking various different nutritional supplements and to reduce the risk of interactions with nutritional supplements and / or drugs. [Examples]

[0024] The group of anti-metabolic plant peptides disclosed in the first embodiment of the present invention includes a group of peptides, which are multiple functional low-molecular-weight peptides separated from the primary product of a plant raw material, the primary product of which is obtained by sequentially performing a water extraction step and a supercritical fluid extraction step on bitter melon. The group of anti-metabolic plant peptides are peptides shown in the wavelength range (L1) to (L6) in Figure 1, with retention times between 10.5 and 25.5 minutes, and molecular weights between 300 Da and 3000 Da, respectively.

[0025] Here, wavelength ranges (L1) to (L6) are obtained by performing a pretreatment step on the primary product of the plant raw material and then analyzing it using a high-performance liquid chromatograph under predetermined analytical conditions. The analytical conditions include the following: detection wavelength of 220 nm, separation column of C18 column (RP-C18), column temperature of 60°C, eluent A is 5% acetonitrile containing 0.10% trichloroacetic acid, eluent B is 95% acetonitrile containing 0.085% trichloroacetic acid, and the mobile phase includes 10-20% eluent B used for 0-10 minutes, 20-30% eluent B used for 10-25 minutes, and 30-60% eluent B used for 20-60 minutes.

[0026] The retention time for wavelength range (L1) is 10.5 to 11.5 minutes, for wavelength range (L2) it is 12.5 to 13.5 minutes, for wavelength range (L3) it is 14.5 to 15.5 minutes, for wavelength range (L4) it is 16.5 to 17.5 minutes, for wavelength range (L5) it is 17.5 to 18.5 minutes, and for wavelength range (L6) it is 24.5 to 25.5 minutes.

[0027] The pretreatment process includes the following steps.

[0028] Step a: The primary product of the plant raw material is dissolved in 30% acetonitrile, and then ultrasonic extraction is performed to obtain the supernatant.

[0029] Step b: Filter the supernatant to obtain a filtrate for high-performance liquid chromatography.

[0030] Each wavelength range (L1) to (L6) in Figure 1 was analyzed by gel permeation chromatography (GPC), and the molecular weight for each wavelength range (L1) to (L6) was estimated by comparison with the GPC chromatogram of the standard samples, confirming that it was between 300 and 3000 Da. The standards used were cytidine (molecular weight 243 Da), vitamin B12 (molecular weight 1350 Da), aprotinin (molecular weight 6500 Da), cytochrome (molecular weight 12000 Da), and myoglobin (molecular weight 17600 Da). The order of appearance of the molecular weight sizes of these substances was myoglobin (10.226 min), cytochrome (10.658 min), aprotinin (11.864 min), vitamin B12 (13.787 min), and cytidine (14.835 min).

[0031] Furthermore, simulated digestion tests were conducted on a group of anti-metabolic plant peptides, and the difference in area percentage in each wavelength range before and after the test was analyzed using high-performance liquid chromatography. The results are shown in Table 1.

[0032] Table 1: Analysis results for each wavelength range (L1) to (L6) in Figure 1. JPEG0007837069000001.jpg52151 [Examples]

[0033] To demonstrate that the group of anti-metabolic plant peptides disclosed in this invention can be stably separated, in the second embodiment disclosed in this invention, various cucurbitaceous plants from different origins, including pumpkin, watermelon, bitter melon, and snake gourd, were prepared, and a water extraction step and a supercritical fluid extraction step were performed sequentially on each to obtain primary products of the plant raw materials. After treating the primary products of each plant raw material according to the above-described pretreatment steps, analysis was performed by high-performance liquid chromatography under the above-described analytical conditions to obtain the chromatograms shown in Figures 2 to 11. Here, in the explanation of each figure, the numbers after the cucurbitaceous plants are used to distinguish between batches or sources of the same cucurbitaceous plant. Subsequently, the content of each wavelength range in each chromatogram was analyzed as shown in Table 2 below.

[0034] As can be seen from the chromatograms in Figures 2 to 11, wavelength ranges (L1) to (L6) appeared with retention times of 10.5 to 25.5 minutes, respectively. Of these, the retention time for wavelength range (L1) was 10.5 to 11.5 minutes, for wavelength range (L2) it was 12.5 to 13.5 minutes, for wavelength range (L3) it was 14.5 to 15.5 minutes, for wavelength range (L4) it was 16.5 to 17.5 minutes, for wavelength range (L5) it was 17.5 to 18.5 minutes, and for wavelength range (L6) it was 24.5 to 25.5 minutes.

[0035] Table 2: Content in wavelength ranges (L1) to (L6) in Figures 2 to 11 JPEG0007837069000002.jpg162167

[0036] As can be seen from the chromatograms disclosed in Figures 1 to 11, the group of anti-metabolic plant peptides disclosed in this invention stably appears in the primary products of the plant raw materials in each batch, and stably appears in any of the different types of plant raw materials. Therefore, it is clear that the group of anti-metabolic plant peptides disclosed in this invention has availability and reproducibility. [Examples]

[0037] The group of anti-metabolic plant peptides disclosed in the third embodiment of the present invention is the same as in the above-described embodiment, but the difference lies in the pretreatment step performed on the primary product of the plant raw material. The specific step is as follows.

[0038] The primary product of the plant raw material is dissolved in 30% acetonitrile, followed by first ultrasonic extraction for 20 minutes. The water bath temperature is lower than room temperature, and the mixture is separated by centrifugation at 9000 rpm for 5 minutes to obtain the first supernatant and first precipitate. The first precipitate is dissolved in 30% acetonitrile, followed by first ultrasonic extraction for 20 minutes. The water bath temperature is lower than room temperature, and the mixture is separated by centrifugation at 9000 rpm for 5 minutes to obtain the second supernatant. The first and second supernatants are collected and filtered through a filtration membrane with a void of 0.20-0.25 μm. The resulting filtrate can be used for subsequent high-performance liquid chromatography.

[0039] In addition, to demonstrate the novelty and uniqueness of the anti-metabolic plant peptides disclosed in this invention, in this example, commercially available bitter melon extracts (comparative samples 1-7) were subjected to the pretreatment method disclosed in the first example of this invention, analyzed by high-performance liquid chromatography under the same analytical conditions, and the chromatograms obtained from comparative samples 1-7 were combined with the chromatogram shown in Figure 1. The results are shown in Figure 12. 。

[0040] Figure 1 2As can be seen from the results, the group of anti-metabolic plant peptides disclosed in the present invention includes peptides in the wavelength range (L1) to (L6), whereas comparative sample 1 does not have wavelength ranges (L1), (L2), and (L6), comparative sample 2 does not have wavelength ranges (L1), (L4), and (L5), comparative sample 3 does not have wavelength ranges (L1) to (L6), comparative sample 4 does not have wavelength ranges (L1) to (L6), comparative sample 5 does not have wavelength ranges (L1) to (L6), comparative sample 6 does not have wavelength ranges (L1), (L3) to (L6), and comparative sample 7 does not have wavelength ranges (L4) to (L6). These results prove that the group of anti-metabolic plant peptides disclosed in the present invention is indeed novel and unique and cannot be obtained by isolation from other plant extracts of the same origin.

[0041] The following is an efficacy test conducted to demonstrate that the group of anti-metabolic plant peptides disclosed in this invention has the effect of treating or improving diseases related to abnormalities in blood pressure, blood glucose, and blood lipids.

[0042] First, the human dose was based on 300 mg / 60 kg adult body weight / day, and converted to a rat dose according to common sense known to those skilled in the art in the field to which this invention belongs. The following tests were then conducted according to the designs of various animal models. The test period for all tests was 8 weeks.

[0043] Animal study (1): SD rats were randomly divided into three groups. Group 1 consisted of normal rats, while Groups 2 and 3 were rats that were type 2 diabetic models induced by the simultaneous administration of the drug STZ (25 mg / kg body weight) and a high-fat diet, respectively. Group 3 was continuously administered the anti-metabolic plant peptide group disclosed in this invention throughout the study period. After the end of the 8th week of the study, fasting blood glucose levels and glycated hemoglobin levels were examined in each group of mice. The results are shown in Figures 13 and 14.

[0044] Animal study (2): SD rats were randomly divided into three groups. Group 1 consisted of normal rats, while Groups 2 and 3 consisted of rats that were type 1 diabetic models induced by the drug STZ (75 mg / kg body weight). Group 3 was continuously administered the anti-metabolic plant peptide group disclosed in this invention throughout the study period. After the end of the 8th week of the study, fasting blood glucose levels were measured in the mice of each group. The results are shown in Figure 15.

[0045] Animal study (3): SD rats were randomly divided into two groups. Both groups were given a high-fat diet, and after increasing the body weight of both groups by 10%, an 8-week study was conducted. The high-fat diet was maintained throughout the study period, except that only the rats in the second group were given the anti-metabolic plant peptide group disclosed in this invention during the study period. After the study, the body weight, body fat, blood triglycerides, blood total cholesterol, and blood LDL cholesterol of the rats in each group were examined. The results are shown in Figures 16 to 20.

[0046] Furthermore, multiple subjects were gathered and randomly divided into two groups. Group 1 did not receive the anti-metabolic plant peptides disclosed in this invention, while Group 2 received the anti-metabolic plant peptides disclosed in this invention (300 mg / 60 kg adult body weight / day). Each subject in each group was given 75 g of glucose on an empty stomach, and blood glucose levels were measured at 0, 30, 60, 90, and 120 minutes after ingestion. The area under the curve of the oral glucose tolerance test (OGTT AUC) was also analyzed 2 hours later. The results are shown in Figures 21 and 22.

[0047] The results of the animal and human trials mentioned above are summarized in Table 3 below. 3As can be seen from the results in Figures 12 to 21, the group of anti-metabolic plant peptides disclosed in this invention has an improving effect on both congenital and acquired blood glucose metabolic disorders. Furthermore, even under conditions of continuous high-fat diets, it was possible to effectively reduce the effects of high-fat diets on blood lipids and cholesterol. From this, it can be seen that the group of anti-metabolic plant peptides disclosed in this invention can indeed simultaneously and effectively improve abnormal metabolic indicators, simultaneously improve symptoms related to hyperglycemia, hyperlipidemia, and obesity, and achieve a reduction in the risk of developing diseases caused by the aforementioned metabolic disorders.

[0048] Table 3: Analysis results of efficacy JPEG0007837069000003.jpg85166

[0049] Furthermore, in order to explain the difference in efficacy when comparing the group of anti-metabolic plant peptides disclosed in the present invention with compositions that do not contain the group of peptides shown in other wavelength ranges (L1) to (L6), the group of anti-metabolic plant peptides of the present invention, comparative sample 1, and comparative sample 4 were each administered to rats of a type 2 diabetes model, and then the body weight and FB of the rats in each experimental group were measured. G The changes in HbA1c were analyzed separately. The results are shown in the table. 4 As shown above. For details on the experimental procedure, please refer to the explanation of the animal test (1) above. Also, see Table 4 The data within the graph represents the percentage change in each experimental group compared to diabetic model rats.

[0050] Furthermore, after administering the anti-metabolic plant peptide group of the present invention and comparative sample 4 to rats of a high-fat diet model, changes in body weight, body fat, triglycerides, and total cholesterol in each experimental group of rats were analyzed. The results are shown in the table. 5 As shown above. For details on the experimental procedure, please refer to the explanation of the animal test (3) above. Also, see Table 5 The data within the graph represents the percentage change in each experimental group compared to diabetic model rats.

[0051] The results in Tables 4 and 5 demonstrate that the anti-metabolic plant peptide group disclosed in the present invention has a significant effect in improving blood glucose and blood lipid control compared to compositions that do not contain the peptide group shown in other wavelength ranges (L1) to (L6).

[0052] 4: Percentage change in each experimental group compared to diabetic model rats JPEG0007837069000004.jpg28128

[0053] Table 5: Percentage change in each experimental group compared to diabetic model rats JPEG0007837069000005.jpg26128

[0054] Furthermore, the blood pressure-lowering activity of the anti-metabolic plant peptides disclosed in this invention was analyzed through LC angiotensin-converting enzyme (ACE) activity analysis using liquid chromatography. Specifically, although the peptides use hippryl-L-histidyl-L-leucine (HHL, Hip-His-Leu) as a substrate, ACE action generates hippuric acid (HA, hippuric acid) and histidylleucine (His-Leu). Therefore, if ACE activity is inhibited after the addition of the test sample and the amount of hippuric acid and histidylleucine produced decreases, it means that the test sample can effectively treat or improve hypertension. In this example, the blood pressure-lowering ability of the anti-metabolic plant peptides disclosed in this invention was analyzed by comparing the amount of hippuric acid produced with and without the addition of the anti-metabolic plant peptides disclosed in this invention. Here, the inhibition rate of ACE activity was calculated by measuring the amount of hippuric acid produced (integrated area) using HPLC analysis. The test results showed that the group treated with the anti-metabolic plant peptides disclosed in this invention (10 mg / mL) had a blood pressure reduction of 30.63% compared to the control group not treated with the anti-metabolic plant peptides disclosed in this invention. This demonstrates that the anti-metabolic plant peptides disclosed in this invention do indeed have the ability to lower blood pressure and can be used in the preparation of compositions for treating or improving hypertension and related diseases.

Claims

1. The isolated group of anti-metabolic plant peptides is isolated from the primary product of a cucurbitaceous plant raw material, and the primary product of the cucurbitaceous plant raw material is obtained by sequentially performing water extraction and supercritical fluid extraction on the cucurbitaceous plant raw material. The aforementioned group of antimetabolic plant peptides includes peptides with molecular sizes between 700 Da and 2400 Da, as shown in wavelength ranges (L1) to (L6) in a high-performance liquid chromatogram, with retention times of 10.5 to 11.5 minutes for wavelength range (L1), 12.5 to 13.5 minutes for wavelength range (L2), 14.5 to 15.5 minutes for wavelength range (L3), 16.5 to 17.5 minutes for wavelength range (L4), 17.5 to 18.5 minutes for wavelength range (L5), and 24.5 to 25.5 minutes for wavelength range (L6). The high-performance liquid chromatogram was obtained by performing a pretreatment step on the primary product of the cucurbitaceous plant raw material, and then analyzing it using a high-performance liquid chromatograph under predetermined analytical conditions. The aforementioned analytical conditions are as follows: detection wavelength is 220 nm, separation column is C18 column (diameter 4.6 mm x length 250 mm, flow rate approximately 1.0 ml / min), column temperature is 60°C, eluent A is 5% acetonitrile containing 0.10% trichloroacetic acid, eluent B is 95% acetonitrile containing 0.085% trichloroacetic acid, and the mobile phase includes 10-20% eluent B used for 0-10 minutes, 20-30% eluent B used for 10-25 minutes, and 30-60% eluent B used for 20-60 minutes. The aforementioned pretreatment step is Step a: After dissolving the primary product of the cucurbitaceous plant raw material in 30% acetonitrile, ultrasonic extraction is performed to obtain the supernatant. A group of separated anti-metabolic plant peptides, comprising step b, which involves filtering the supernatant to obtain a filtrate for high-performance liquid chromatography.

2. The separated group of anti-metabolic plant peptides according to claim 1, wherein in step b, filtration is performed using a filter material with voids of 0.20 to 0.25 μm.

3. The use of the isolated group of anti-metabolic plant peptides described in claim 1 or claim 2 in the preparation of a composition for preventing or treating hyperlipidemia, hypertension, and hyperglycemia.

4. The use according to claim 3, wherein the human dose of the isolated group of anti-metabolic plant peptides contained in the composition is 5 mg / kg / day.

5. Use of the isolated group of anti-metabolic plant peptides described in claim 1 or claim 2 in the preparation of a diet composition.

6. The use according to claim 5, wherein the human dose of the isolated group of anti-metabolic plant peptides contained in the composition is 5 mg / kg / day.

Images